Skip to main content

Table 5 The reasons for apatinib dose change (safety set, n = 32)

From: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Reasons Dose escalation failure (n = 10) Discontinuation (n = 7)
Hypertension, n (%) 5 (50.0%) 1 (14.3%)
Neutropenia, n (%) 4 (40.0%) 0
Thrombocytopenia, n (%) 2 (20.0%) 2 (28.6%)
Fatigue, n (%) 3 (30.0%) 0
Anorexia, n (%) 3 (30.0%) 0
Hand-foot syndrome, n (%) 1 (10.0%) 0
Elevation of ALT/AST, n (%) 0 2 (28.6%)
Emergency surgery, n (%) 0 1 (14.3%)
Disease progression, n (%) 0 1 (14.3%)
  1. ALT alanine aminotransferase, AST aspartate aminotransferase